Masimo Corporation

Masimo Corporation

Masimo Corporation

Overview
Date Founded

1996

Headquarters

52 DISCOVERY, IRVINE, CA, 92618

Type of Company

Public

Employees (Worldwide)

4,500

Industries

Medical Products & Equipment
Industrial Machinery & Manufacturing
Hospitals & Patient Services
Biotechnology

Company Description

Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo rainbow® SET Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb®) monitoring technology. These new rainbow® technologies are expected to open new markets and significantly expand the company’s growth opportunities. Joe Kiani founded Masimo in 1989 as a private "garage start-up" company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry. Today, Masimo has grown into a successful publicly traded medical technology company employing over 2,500 people worldwide with product revenues that have increased 4-fold in the last five years. In addition, the company has technology license and OEM agreements with leading patient monitoring manufacturers spanning the globe including Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs, and Zoll. Masimo is not only the inventor of Measure-through Motion and Low Perfusion pulse oximetry and Pulse CO-Oximetry technologies, but is also the market-leading pulse oximetry technology solution. In 1995, Masimo debuted Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo SET—a breakthrough in pulse oximetry technology that virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate that Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that measures many blood constituents that previously required invasive procedures. Masimo rainbow SET continuously and noninvasively measures total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®) and pleth variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), enabling early detection and treatment of potentially life-threatening conditions. For more than 20 years now, Masimo has been focused on a singular mission—to create noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and applications. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making

Contact Data
Trying to get in touch with decision makers at Masimo Corporation? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Executive Vice President, Finance & Chief Financial Officer

Chief Operating Officer

Executive Vice President, General Counsel

Executive Vice President & Chief Information Officer

Chief Scientific Officer

Chief Accounting Officer

President-Japan

President-Europe, Middle East & Africa

Senior Director

Board of Directors

Founder at Masimo Corporation

Former Senator from Iowa

Former Senior Vice President & Chief Financial Officer at Conceptus, Inc.

Former Chief Executive Officer & Director at Ebb Therapeutics, Inc.

Partner at Camber Capital Management LLC

Vice President, Semiconductor Products Section at 3Com Corporation

Former Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities, Inc.

Paths to Masimo Corporation
Potential Connections via
Relationship Science
You
Masimo Corporation
Owners & Shareholders
Details Hidden

Scout Investments offers an array of investment strategies listed below, as well as customized strategies and socially responsible portfolios. Their equity strategies include: International Equity, International Equity ADR, Mid Cap Equity, and Small Cap Equity. The firm's fixed income strategies include: Core Fixed Income, Core Plus Fixed Income, Intermediate Fixed Income, Long Duration Fixed Income, Low Duration Fixed Income, Ultra Low Duration Fixed Income, and Unconstrained Fixed Income. Scout Investments provides fixed income strategies through their Reams Asset Management division.

Details Hidden

HealthCor Management's funds seek to preserve capital and generate risk-adjusted capital growth. The funds pursue a fundamental-driven long/short equity strategy with a primary focus on the global healthcare and life sciences sector. HealthCor employs a bottom-up fundamental selection of best long and short ideas. The firm conducts daily monitoring of top-down, portfolio-level analysis, including the following: concentration of investments: liquidity; price target and stop loss monitoring, leverage, and hedging. In addition, HealthCor has adopted a Socially Responsible Investment Policy outlining their practical integration of environmental, social and governance (\"ESG\") considerations into their investment process.

Details Hidden

MGI's investment strategies include equities, fixed income and alternatives. For equities, the firm incorporates a range of both long-only and long/short strategies - covering most major stock markets, and a number of different investment styles. They believe that success in equity investing requires a high degree of specialism, with investment approaches honed to reflect the distinctive nuances of diverse stock markets. MGI's fixed income team offers capabilities in multi-sector bonds (including both absolute-return and market-relative strategies), corporate bonds, including financials contingent capital bonds (often known as \"CoCos\") and both local- and hard-currency emerging market bonds. The portfolio managers and analysts who specialize in these areas collaborate to share ideas on strategy, positioning and research - as well as developing a holistic view of the fixed income market. For alternatives, the firm believes that allocating to alternatives can provide a stable cornerstone for building a successful portfolio. Their offering includes capabilities in equity market neutral, directional equity long/short, gold and silver, style premia and systematic positive skew (short term managed futures) strategies. The strategies aim to deliver strong risk-adjusted returns while limiting downside, across a range of annualized target volatilities.

Recent Transactions
Details Hidden

Masimo Corporation purchases Masimo Sweden AB

Details Hidden

Masimo Corporation purchases Spire Semiconductor LLC from Spire Corp.

Details Hidden

Masimo Corporation purchases SEDLine, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onMasimo Corporation purchases Masimo Sweden AB

Underwriter

Advised onMasimo Corporation issued Common Stock

Underwriter

Advised onMasimo Corporation issued Common Stock

Legal Advisor

Advised onMasimo Corporation purchases Masimo Sweden AB

Associate, Corporate Department

Advised onMasimo Corporation purchases Masimo Sweden AB

Clients

Medtronic Plc is a medical technology company, which develop, manufacture, distribute, and sell device-based medical therapies and services. It also provides services to the hospitals, physicians, clinicians, and patients. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist of three divisions: Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral Vascular. The Minimally Invasive Technologies Group segment comprises of three divisions: Surgical Innovations and Respiratory, Gastrointestinal, and Renal. The Restorative Therapies Group contains four divisions: Spine, Brain, Specialty Therapies, and Pain Therapies. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Cardinal Health, Inc. engages in the provision of pharmaceutical and medical products. It operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The company was founded by Robert D. Walter in 1971 and is headquartered in Dublin, OH.

Founded in Richmond, Virginia, in 1882, Owens & Minor is the nation’s leading distributor of medical and surgical supplies to the acute-care market and a leading provider of healthcare supply chain management solutions. For the first 110 years, our company provided pharmaceutical, and medical and surgical supplies to drugstores and hospitals throughout selected areas of the United States. In 1992, we made a decision to sell our wholesale drug business and focus entirely on the medical/surgical marketplace. This wise decision has paid huge dividends. Today, our 5,100 teammates in 55 distribution centers and our home office serve 4,500 hospitals, integrated healthcare systems, alternate care locations, and the federal government with a comprehensive offering of medical and surgical products. The majority of our sales are consumable goods, such as disposable gloves, dressings, endoscopic products, needles and syringes, sterile procedure trays, surgical products and gowns, and urological and wound-closure products. We have established a great reputation for providing superior, world-class service and continually strive to exceed our customers’ expectations. We understand that if we take great care of our customers, they will take great care of us. Owens & Minor’s common shares are traded on the New York Stock Exchange under the symbol OMI. Our goal is to deliver long-term value to our shareholders and we have paid dividends consistently since 1930. Delivering the difference is our mantra, and we strive every day to live up to that.

Key Stats and Financials As of 2018
Market Capitalization
$7.14B
Total Enterprise Value
$5.36B
Earnings Per Share
$3.45
Revenue
$858M
Net Profit
$194M
EBITDA
$230M
EBITDAMargin
26.75%
Total Debt
$0
Total Equity
$969M
Enterprise Value Sales
6.25x
Enterprise Value EBITDAOperating
23.36x
TEVNet Income
27.71x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
11.26%
Five Year Compounded Annual Growth Rate Of Revenue
9.42%
Non-Profit Donations & Grants
$5,000 +
2016
$5,000 - $10K
2014
Non-Profit Donations & Grants Received
Political Donations
$6,300
2014
$6,800
2014
$4,100
2013
Investors
Details Hidden

Camden Partners Private Equity:Camden Partners invests in lower middle market companies located in the US with an enterprise value of $25 - $250 million. The fund focuses on companies with positive cash flow, recurring revenue, low leverage, revenues of $10 million to $100 million and EBITDA up to $10 million. It targets companies operating in the fields of education, healthcare and business services. It provides financing for acquisitions, recapitalizations and growth stage capital requirements. It acquires controlling interests and takes a seat on the board of directors.It also provides financing that combines debt with warrants and with various types of preferred securities and also invest in micro-cap public companies.Camden Partners Nexus Strategy:Camden Partners Nexus Fund LP seeks investment opportunities in companies located in the US. The fund targets companies operating in the fields of technology services. It provides financing for seed-stage capital requirements and invests $500,000 to $2,500,000.

Suppliers
Amazon.com, Inc. Management Consulting | Seattle, Washington

Amazon.com, Inc. engages in the provision of online retail shopping services. It operates through the following business segments: North America, International, and Amazon Web Services (AWS). The North America segment includes retail sales of consumer products and subscriptions through North America-focused websites such as www.amazon.com and www.amazon.ca. The International segment offers retail sales of consumer products and subscriptions through internationally-focused websites. The Amazon Web Services segment involves in the global sales of compute, storage, database, and AWS service offerings for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Competitors
Medtronic Plc Medical Products & Equipment - Dublin, DU

Medtronic Plc is a medical technology company, which develop, manufacture, distribute, and sell device-based medical therapies and services. It also provides services to the hospitals, physicians, clinicians, and patients. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist of three divisions: Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral Vascular. The Minimally Invasive Technologies Group segment comprises of three divisions: Surgical Innovations and Respiratory, Gastrointestinal, and Renal. The Restorative Therapies Group contains four divisions: Spine, Brain, Specialty Therapies, and Pain Therapies. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Masimo Corporation. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Masimo Corporation's profile does not indicate a business or promotional relationship of any kind between RelSci and Masimo Corporation.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/masimo-corporation-26636
  • https://relationshipscience.com/organization/masimo-corporation-26636